Beyond Glycaemia- Weight Reduction Is the New Additional Therapeutic Endpoint in T2D Dr. Kamal Kant Kohli7 March 2026 10:59 AM ISTIndia bears a disproportionate share of the global diabetes burden, with 89.8 million adults living with T2DM against a worldwide estimate of 589...
PRO-ACT Study Shows Better Outcomes with Minoxidil PRCT for Androgenetic Alopecia Dr. Bhumika Maikhuri7 March 2026 10:00 AM ISTA recent clinical study has highlighted the potential of a novel Minoxidil formulation integrated with bioactive peptides for the management of...
Presence to Precision: Moving beyond Omnichannel - Gurpinder Singh Gurpinder Singh6 March 2026 3:17 PM ISTThe pharma industry's legacy is based on constant innovation, particularly in the R&D space. Undoubtedly, science has made strides in treating...
Expert Perspectives on the COMBINE Angina Study - with Dr Hanish Gupta Dr. Bhumika Maikhuri28 Feb 2026 11:15 AM ISTIn this video, Dr. Hanish Gupta, Senior Consultant Physician and Cardiologist, Life Aid Clinic, New Delhi, shares his clinical insights as an...
Massive Medical Negligence of the government - Dr Rajeev Joshi Dr Rajeev Joshi26 Feb 2026 4:06 PM ISTI was stunned to read a news article in Times of India dated 21-02-2026 titled "Ghost pathologist in MMR : dead doctor signed 'several' reports, which...
Empagliflozin & Sitagliptin - Landmark Trials Revisited in 2026 Dr. Bhumika Maikhuri23 Feb 2026 10:30 AM ISTIn this episode of Diabetes Wellness Forum, titled, "Empagliflozin & Sitagliptin - Landmark Trials Revisited in 2026", Dr Nandita Mohan from...
Therapeutic Application of Empagliflozin, Sitagliptin, and Metformin for Advancing Overall Wellness in T2D: Evidence Review for Practitioners in 2025 Dr. Manoj Chadha19 Feb 2026 10:35 AM ISTHyperglycemia in T2D plays a pivotal role in diabetic microvascular complications; however, reducing HbA1c offers only modest benefit in mitigating...
Aspirin Benefit for Primary Prevention in High-Risk T2D - Observational Analysis: AHA 2025 Abstract Dr. Nitin Gudage17 Feb 2026 12:00 PM ISTFor years, the medical community has sought the ideal balance for aspirin in primary prevention. New evidence from the American Heart Association...
Beta-Blockers Cut Cardiovascular Events by 25% in Post-MI Patients with Mildly Reduced LVEF: Meta-Analysis Prem Aggarwal16 Feb 2026 12:01 PM ISTLong-term oral Beta-blocker therapy, including bisoprolol, metoprolol, and carvedilol, reduces the composite endpoint of all-cause death, new...
Lifestyle-Linked CV Risk: Where Does Aspirin Fit? Dr. Nishant Tripathy13 Feb 2026 12:45 PM ISTIndia faces a rapidly evolving cardiometabolic risk landscape, with overweight and obesity affecting 23.5% and 6.7% of adults, alongside escalating...
Redefining Diabetes Management With Dapagliflozin and Sitagliptin FDC: An Early, Effective and Sustainable Option For T2D Management With Risk Factors Dr. Vaishali Deskhmukh12 Feb 2026 12:40 PM ISTType 2 diabetes in Indians follows a distinct and more aggressive trajectory, marked by higher insulin resistance, early Beta-cell dysfunction, lower...
Considering Triple Agents in Glucose Control - Application & Safety Considerations in 2026 Dr. Bhumika Maikhuri11 Feb 2026 11:00 AM ISTIn this episode of The Diabetes Wellness Forum, titled "Considering Triple Agents-Application & Safety Considerations in 2026," Dr Nandita Mohan...
